<DOC>
	<DOCNO>NCT00558363</DOCNO>
	<brief_summary>ARI109924 2-year , multicentre , randomise , double-blind , placebo-controlled trial assess efficacy safety dutasteride extend time prostate specific antigen ( PSA ) double men treat clinically localised prostate cancer ( PCa ) radical therapy ( radical prostatectomy , primary radiotherapy salvage radiotherapy ) curative intent experience biochemical failure ( PSA rise ) afterwards without sign symptom metastasis .</brief_summary>
	<brief_title>ARTS - AVODART After Radical Therapy For Prostate Cancer Study</brief_title>
	<detailed_description>A Randomised , Double-Blind , Placebo-Controlled Trial Assessing Efficacy Safety Dutasteride ( AVODART™ ) 0.5 mg Extending Time PSA Doubling Men Prostate Cancer Biochemical Failure ( PSA increase ) Radical Therapy Curative Intent ( ARTS - AVODART Radical Therapy prostate cancer Study )</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Patients eligible enrolment study must meet following criterion : Males &lt; 85 year age No clinically relevant abnormal finding screen ECG Patients asymptomatic PSA failure follow radical therapy curative intent clinically localised prostate cancer . PSA failure define : After primary radiotherapy : 3 rise PSA level nadir PSA , determination least 4 week apart final PSA level ≥2 ng/mL nadir PSA Time radiotherapy least 1 year termination radiotherapy treatment After radical prostatectomy without salvage radiotherapy : 3 rise PSA level nadir PSA , determination least 4 week apart PSA level ≥0.2 ng/mL final PSA level ≥0.4 ng/mL ( nadir PSA define low PSA value achieve therapy ) Serum PSA level : ≥2 ng/mL ≤20ng/mL primary radiotherapy patient ≥0.4 ng/ml ≤10ng/ml radical prostatectomy without salvage radiotherapy patient PSADT &gt; 3 month ≤24 month Clinical stage T1T3a N0 M0 Nonmetastatic prostate cancer , confirm negative bone scan perform within 6 month prior randomisation ( Visit 2 ) 3 . No evidence local recurrence radical prostatectomy salvage radiotherapy patient Expected survival ≥2 year Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 ( see Appendix 1 ) Miscellaneous : Able swallow retain oral medication Able willing participate full 2 year study Able read write ( MAXPC questionnaire selfadministered ) , understand instruction relate study procedure give write informed consent In France , patient eligible inclusion study either affiliate beneficiary social security category . Any unstable serious coexist medical condition ( ) include limited myocardial infarction , coronary bypass surgery , unstable angina , cardiac arrhythmia , clinically evident congestive heart failure cerebrovascular accident within 6 month prior Visit 1 , uncontrolled diabetes peptic ulcer disease uncontrolled medical management Abnormal liver function test ( great 2 time upper limit normal [ ULN ] alanine aminotransferase [ ALT ] , aspartate aminotransferase [ AST ] alkaline phosphatase [ ALP ] &gt; 1.5 x ULN bilirubin ) . Serum creatinine &gt; 1.5 x ULN History another malignancy within 5 year could affect diagnosis prostate cancer History current evidence drug alcohol abuse within 12 month prior Visit 1 History illness ( include psychiatric ) , opinion investigator , might confound result study pose additional risk patient Known hypersensitivity 5AR inhibitor drug chemically relate dutasteride Disease characteristic : Serum PSA level &gt; 20 ng/mL primary radiotherapy patient &gt; 10 ng/mL radical prostatectomy without salvage radiotherapy patient PSADT ≤3 month &gt; 24 month Biochemical failures post brachytherapy patient Clinical stage N+ M+ Patient previously treat prostate cancer follow : Chemotherapy Oestrogens ( e.g . megestrol , medroxyprogesterone , cyproterone , Diethylstilbestrol [ DES ] ) Drugs antiandrogenic property ( e.g . spironolactone &gt; 50mg/day , flutamide , bicalutamide , ketoconazole , progestational agent ) , ( except use adjuvancy neoadjuvancy context primary radical treatment case use 6 month complete least 1 year Visit 1 [ Note : use topical ketoconazole permit prior study use cimetidine permit prior study entry ] GnRH analogue ( e.g. , leuprolide , goserelin ) except use adjuvancy neoadjuvancy context primary radical treatment ( case use 6 month finalise least 1 year Visit 1 ) Orchiectomy Concomitant medication : Glucocorticoids , except inhaled topical , permit within 3 month prior Visit 1 study Current and/or previous use finasteride ( Proscar , Propecia ) dutasteride ( GI198745 , AVODART™ ) exposure within 6 month prior Visit 1 Anabolic steroid within 6 month prior Visit 1 Participation investigational market drug trial within 30 day prior Visit 1 time study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>AVODART</keyword>
	<keyword>PSA</keyword>
	<keyword>dutasteride</keyword>
	<keyword>PSADT</keyword>
	<keyword>Prostate specific antigen</keyword>
	<keyword>radical therapy</keyword>
	<keyword>double time</keyword>
</DOC>